Milrinone versus Dobutamine as Supportive Agent for Right Ventricular Dysfunction after Cardiopulmonary Bypass: A...

Area of Science:

• Cardiology
• Cardiac Surgery
• Pharmacology

Background:

• Right ventricular (RV) dysfunction is a common complication after cardiopulmonary bypass (CPB).
• Choosing the optimal inotrope for RV support is critical for patient outcomes.

Purpose of the Study:

• To compare the efficacy and safety of milrinone versus dobutamine in treating RV dysfunction post-CPB.
• To evaluate effects on echocardiographic measures and clinical outcomes.

Main Methods:

• A randomized, open-label, parallel-group controlled trial involving 88 adult patients with RV systolic dysfunction post-CPB.
• Patients received either milrinone or dobutamine.
• Co-primary outcomes included mechanical ventilation duration and tricuspid annular plane systolic excursion (TAPSE) change over 24 hours.

Main Results:

• Both milrinone and dobutamine improved TAPSE significantly over 24 hours.
• Milrinone showed a modest, potentially clinically uncertain, increase in TAPSE compared to dobutamine.
• Milrinone required significantly more norepinephrine, while other clinical outcomes were similar.
• Exploratory analysis suggested milrinone may be superior in patients with elevated pulmonary artery systolic pressure (>40 mmHg).

Conclusions:

• Milrinone and dobutamine provide comparable overall RV recovery post-CPB.
• Milrinone's increased norepinephrine requirement and uncertain TAPSE benefit warrant consideration.
• Further research is needed to confirm milrinone's potential advantage in specific patient populations with pulmonary hypertension.